Earnings Releases·Nov 12, 2026, 7:07 AM ET

Parabilis Medicines — Third Quarter 2026 Earnings Summary

Revenue reached $2.1 million from collaboration agreements versus $0 in the prior-year period, while net loss widened to $44.5 million from $33.5 million due to increased R&D ($45.6M vs $28.2M) and G&A ($11.3M vs $6.6M) expenses.
The company secured a robust liquidity position with cash, equivalents, and marketable securities totaling $1.1 billion as of September 30, 2026, up from $27.7 million at year-end 2025, sufficient to fund operations into 2030.
Strategic progress includes FDA alignment on the PEDESTAL Phase 3 registrational trial design for desmoid tumors, with initiation planned for the first half of 2027 and topline results expected in 2029.
Pipeline updates revealed a 72.2% objective response rate in Phase 1/2 desmoid tumor data, early activity in FAP, ACP, and HCC, and a new cost-shared clinical collaboration with Revolution Medicines for MSS CRC.
No specific financial guidance was issued for future quarters, though management confirmed confidence in the PEDESTAL trial timeline and highlighted the advancement of the Helicon platform through preclinical programs and a Regeneron collaboration.